Moreover, this overexpression is related to the grade of the tumor; the levels of expression of G6PD were in the range of 5 to 245-fold in CNS WHO grade 1 and 2 gliomas compared to CNS WHO grade 3 and 4 gliomas, with a range of 2197 to 4946-fold. Here, G6PD is linked to central nervous system cancer.